CN107614061A - 用于治疗与疼痛有关的偏头痛和病症方法和组合物 - Google Patents

用于治疗与疼痛有关的偏头痛和病症方法和组合物 Download PDF

Info

Publication number
CN107614061A
CN107614061A CN201580075227.5A CN201580075227A CN107614061A CN 107614061 A CN107614061 A CN 107614061A CN 201580075227 A CN201580075227 A CN 201580075227A CN 107614061 A CN107614061 A CN 107614061A
Authority
CN
China
Prior art keywords
composition
migraine
pain
ketoprofen
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580075227.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·弗兰加基斯
W·鲍尔
W·利特克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ake Lies Therapy Co
Original Assignee
Ake Lies Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ake Lies Therapy Co filed Critical Ake Lies Therapy Co
Publication of CN107614061A publication Critical patent/CN107614061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201580075227.5A 2014-12-01 2015-12-01 用于治疗与疼痛有关的偏头痛和病症方法和组合物 Pending CN107614061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085943P 2014-12-01 2014-12-01
US62/085,943 2014-12-01
PCT/US2015/063220 WO2016089893A1 (en) 2014-12-01 2015-12-01 Methods and compositions for treating migraine and conditions associated with pain

Publications (1)

Publication Number Publication Date
CN107614061A true CN107614061A (zh) 2018-01-19

Family

ID=56092337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580075227.5A Pending CN107614061A (zh) 2014-12-01 2015-12-01 用于治疗与疼痛有关的偏头痛和病症方法和组合物

Country Status (6)

Country Link
US (3) US20170266106A1 (enExample)
EP (1) EP3226972A4 (enExample)
JP (2) JP2017536421A (enExample)
CN (1) CN107614061A (enExample)
CA (1) CA3006962A1 (enExample)
WO (1) WO2016089893A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110432888A (zh) * 2019-08-15 2019-11-12 任鹏宇 一种前庭神经权重信息编码神经元的筛选方法
CN115605197A (zh) * 2019-11-13 2023-01-13 特默罗制药股份有限公司（Us） 罗非考昔的新剂型和相关方法
CN115697316A (zh) * 2020-04-21 2023-02-03 东佩制药股份公司 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途
CN115998724A (zh) * 2023-03-28 2023-04-25 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途
US11872206B2 (en) 2018-11-21 2024-01-16 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107789343A (zh) * 2017-11-08 2018-03-13 莫玉艳 一种治疗偏头痛的药物及其制备方法
KR102696819B1 (ko) * 2019-02-22 2024-08-20 페어 테라퓨틱스 (유에스), 인코포레이티드 편두통들과 관련된 증상들의 치료를 위한 시스템들 및 방법들
KR20230051117A (ko) * 2020-01-10 2023-04-17 브리오리 바이오테크 인코포레이티드 로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법
WO2022147155A1 (en) * 2020-12-31 2022-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20240049578A (ko) * 2021-08-16 2024-04-16 세레신 인코포레이티드 트리카프릴린을 이용한 편두통 및 관련 두통 증상 치료 방법
EP4603145A3 (en) * 2022-11-23 2025-11-19 Medicon Pharmaceuticals, Inc. Treating pain associated with central sensitization
WO2025111078A1 (en) * 2023-11-21 2025-05-30 Medicon Pharmaceuticals, Inc. Oral administration of compounds for treating pain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040537A1 (en) * 1996-11-12 2003-02-27 Pozen Inc. Treatment of migraine headache
US6896898B1 (en) * 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
WO2008054788A2 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
WO2011075688A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20140088195A1 (en) * 2012-09-27 2014-03-27 Achelios Therapeutics, Inc. Topical ketoprofen composition

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759980A (en) * 1969-05-26 1973-09-18 Stockton Chemicals Inc Salicylates
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60155111A (ja) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc 安定なケトプロフェン含有外用経皮製剤
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CA2108288C (en) 1991-04-19 2003-09-16 Jill P. Adler-Moore Liposomal cyclosporin formulation and process for the preparation thereof
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5667799A (en) 1995-10-30 1997-09-16 Caldwell; Larry J. Method for treating headache pain with topical local anesthetic compositions
CN1102852C (zh) 1995-11-13 2003-03-12 皮特迈国际有限公司 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6139861A (en) 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
US20020143047A1 (en) 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
ATE404193T1 (de) 2001-06-05 2008-08-15 Ronald Aung-Din Topische migränetherapie
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
EP2907503A1 (en) 2003-04-10 2015-08-19 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20050019354A1 (en) 2003-07-23 2005-01-27 Perricone Nicholas V. Topical benfotiamine treatments
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
CA2563670C (en) 2004-04-19 2014-09-16 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
WO2006122123A2 (en) 2005-05-09 2006-11-16 Levin Bruce H Methods of alleviating disorders and their associated pain
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
CA2629421A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin tricyclic cgrp receptor antagonists
US20090312435A1 (en) 2006-08-30 2009-12-17 Auspex Pharmaceuticals, Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
DK2459183T3 (en) 2009-07-27 2016-01-18 Nocicepta Llc Methods for the treatment of pain
AU2010330813B2 (en) 2009-12-18 2016-04-28 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
JP5944325B2 (ja) 2009-12-18 2016-07-05 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 皮膚の炎症を治療するための方法及び組成物
RU2589697C2 (ru) 2009-12-18 2016-07-10 Экзодос Лайф Сайенсиз Лимитед Партнершип Способы получения стабильных жидких лекарственных препаратов и их композиции
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
EP2818120A4 (en) 2012-02-20 2015-10-21 Univ Keio CENTRAL SENSITIZING DIAGNOSTIC DEVICE AND METHOD OF OPERATING SAME
US8617569B2 (en) * 2012-03-12 2013-12-31 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites
CN104936582B (zh) 2012-12-21 2018-12-21 帝国制药美国股份有限公司 用于激素和其他药剂的经皮传送的组合物和方法
JP2018537503A (ja) 2015-12-16 2018-12-20 アケリオス セラピューティクス，インコーポレーテッド 末梢神経障害を治療するための方法及び組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040537A1 (en) * 1996-11-12 2003-02-27 Pozen Inc. Treatment of migraine headache
US6896898B1 (en) * 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
WO2008054788A2 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
WO2011075688A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US20140088195A1 (en) * 2012-09-27 2014-03-27 Achelios Therapeutics, Inc. Topical ketoprofen composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DANIELA A. G.GONCALVES 等: "How to Investigate and Treat: Migraine in Patients", 《CURR PAIN HEADACHE REP》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872206B2 (en) 2018-11-21 2024-01-16 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
CN110432888A (zh) * 2019-08-15 2019-11-12 任鹏宇 一种前庭神经权重信息编码神经元的筛选方法
CN110432888B (zh) * 2019-08-15 2021-11-23 任鹏宇 一种前庭神经权重信息编码神经元的筛选方法
CN115605197A (zh) * 2019-11-13 2023-01-13 特默罗制药股份有限公司（Us） 罗非考昔的新剂型和相关方法
CN115697316A (zh) * 2020-04-21 2023-02-03 东佩制药股份公司 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途
CN115998724A (zh) * 2023-03-28 2023-04-25 中国人民解放军军事科学院军事医学研究院 布洛芬在抗幻觉作用药物中的新用途

Also Published As

Publication number Publication date
CA3006962A1 (en) 2016-06-09
EP3226972A1 (en) 2017-10-11
US11026882B2 (en) 2021-06-08
US20190216720A1 (en) 2019-07-18
US20170266106A1 (en) 2017-09-21
JP2017536421A (ja) 2017-12-07
US20220125712A1 (en) 2022-04-28
EP3226972A4 (en) 2018-08-08
WO2016089893A1 (en) 2016-06-09
JP2020073563A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
US11026882B2 (en) Methods and compositions for treating migraine and conditions associated with pain
DK2512240T3 (en) Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
AU2014204737B2 (en) Solid solution compositions and use in severe pain
US9980927B2 (en) Use of tapentadol for inhibiting and/or treating depression and anxiety
US10695432B2 (en) Solid solution compositions and use in severe pain
US20220008415A1 (en) Combination Therapy for Male Sexual Dysfunction
US20240207408A1 (en) Solid Solution Compositions and Use in Severe Pain
HK1169919B (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
HK1169919A (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180119